Association between high galectin expression and poor prognosis in hematologic cancers: a systematic review and meta-analysis
ABSTRACTBackground Galectin (Gal) is considered a promising immune checkpoint molecule. More and more studies have shown that high expression levels of galectins in hematologic cancer are positively correlated with poor clinical prognosis. However, the exact prognostic significance of galectins rema...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | Hematology |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2023.2227494 |
_version_ | 1797798158141489152 |
---|---|
author | Haotian Liu Qiuying Dai Yixian Li Zhenfei Tang Tiantian She |
author_facet | Haotian Liu Qiuying Dai Yixian Li Zhenfei Tang Tiantian She |
author_sort | Haotian Liu |
collection | DOAJ |
description | ABSTRACTBackground Galectin (Gal) is considered a promising immune checkpoint molecule. More and more studies have shown that high expression levels of galectins in hematologic cancer are positively correlated with poor clinical prognosis. However, the exact prognostic significance of galectins remains unclear.Methods PubMed, Embase, Web of Science, and Cochrane Library were searched for studies addressing the correlation of galectin expression levels with prognosis of hematologic cancers. Stata software was used to estimate hazard ratios (HR) and 95% confidence intervals (CI).Result Hematologic cancer patients with high galectin expression levels showed poor overall survival (OS, HR = 2.43, 95% CI: 1.95, 3.04), disease-free survival (DFS, HR = 3.29, 95% CI: 1.61, 6.71), and event-free survival (EFS, HR = 2.20, 95% CI: 1.47, 3.29) outcomes. Subgroup analysis revealed that high expression levels of galectins pointed to relatively poor OS in MDS (HR = 5.44, 95% CI: 2.09, 14.18), as compared to AML, CHL and CLL. No correlation was found between galectins and OS in NHL and MM. Among the three galectins, Gal-9 (HR = 3.60, 95% CI: 2.03, 6.38) showed higher correlation with poor prognosis than Gal-1 and Gal-3. In addition, use of peripheral blood (HR = 2.96, 95% CI: 2.07, 4.22) samples and qRT-PCR (HR = 2.80, 95% CI: 1.96, 4.01) method for galectin detection were shown to improve its prognostic correlation in hematologic cancers.Conclusion Meta-analysis revealed high expression of galectins was associated with poor prognosis in hematologic cancer patients and galectins can be considered a promising prognostic predictive marker. |
first_indexed | 2024-03-13T04:00:19Z |
format | Article |
id | doaj.art-b70a1e2078484709b3b0b7a0680153aa |
institution | Directory Open Access Journal |
issn | 1607-8454 |
language | English |
last_indexed | 2024-03-13T04:00:19Z |
publishDate | 2023-12-01 |
publisher | Taylor & Francis Group |
record_format | Article |
series | Hematology |
spelling | doaj.art-b70a1e2078484709b3b0b7a0680153aa2023-06-21T19:14:52ZengTaylor & Francis GroupHematology1607-84542023-12-0128110.1080/16078454.2023.2227494Association between high galectin expression and poor prognosis in hematologic cancers: a systematic review and meta-analysisHaotian Liu0Qiuying Dai1Yixian Li2Zhenfei Tang3Tiantian She4School of Medical Technology, Tianjin Medical University, Tianjin, People’s Republic of ChinaSchool of Medical Technology, Tianjin Medical University, Tianjin, People’s Republic of ChinaSchool of Medical Technology, Tianjin Medical University, Tianjin, People’s Republic of ChinaSchool of Medical Technology, Tianjin Medical University, Tianjin, People’s Republic of ChinaSchool of Medical Technology, Tianjin Medical University, Tianjin, People’s Republic of ChinaABSTRACTBackground Galectin (Gal) is considered a promising immune checkpoint molecule. More and more studies have shown that high expression levels of galectins in hematologic cancer are positively correlated with poor clinical prognosis. However, the exact prognostic significance of galectins remains unclear.Methods PubMed, Embase, Web of Science, and Cochrane Library were searched for studies addressing the correlation of galectin expression levels with prognosis of hematologic cancers. Stata software was used to estimate hazard ratios (HR) and 95% confidence intervals (CI).Result Hematologic cancer patients with high galectin expression levels showed poor overall survival (OS, HR = 2.43, 95% CI: 1.95, 3.04), disease-free survival (DFS, HR = 3.29, 95% CI: 1.61, 6.71), and event-free survival (EFS, HR = 2.20, 95% CI: 1.47, 3.29) outcomes. Subgroup analysis revealed that high expression levels of galectins pointed to relatively poor OS in MDS (HR = 5.44, 95% CI: 2.09, 14.18), as compared to AML, CHL and CLL. No correlation was found between galectins and OS in NHL and MM. Among the three galectins, Gal-9 (HR = 3.60, 95% CI: 2.03, 6.38) showed higher correlation with poor prognosis than Gal-1 and Gal-3. In addition, use of peripheral blood (HR = 2.96, 95% CI: 2.07, 4.22) samples and qRT-PCR (HR = 2.80, 95% CI: 1.96, 4.01) method for galectin detection were shown to improve its prognostic correlation in hematologic cancers.Conclusion Meta-analysis revealed high expression of galectins was associated with poor prognosis in hematologic cancer patients and galectins can be considered a promising prognostic predictive marker.https://www.tandfonline.com/doi/10.1080/16078454.2023.2227494Hematologic cancergalectinprognosissystematic reviewmeta-analysis |
spellingShingle | Haotian Liu Qiuying Dai Yixian Li Zhenfei Tang Tiantian She Association between high galectin expression and poor prognosis in hematologic cancers: a systematic review and meta-analysis Hematology Hematologic cancer galectin prognosis systematic review meta-analysis |
title | Association between high galectin expression and poor prognosis in hematologic cancers: a systematic review and meta-analysis |
title_full | Association between high galectin expression and poor prognosis in hematologic cancers: a systematic review and meta-analysis |
title_fullStr | Association between high galectin expression and poor prognosis in hematologic cancers: a systematic review and meta-analysis |
title_full_unstemmed | Association between high galectin expression and poor prognosis in hematologic cancers: a systematic review and meta-analysis |
title_short | Association between high galectin expression and poor prognosis in hematologic cancers: a systematic review and meta-analysis |
title_sort | association between high galectin expression and poor prognosis in hematologic cancers a systematic review and meta analysis |
topic | Hematologic cancer galectin prognosis systematic review meta-analysis |
url | https://www.tandfonline.com/doi/10.1080/16078454.2023.2227494 |
work_keys_str_mv | AT haotianliu associationbetweenhighgalectinexpressionandpoorprognosisinhematologiccancersasystematicreviewandmetaanalysis AT qiuyingdai associationbetweenhighgalectinexpressionandpoorprognosisinhematologiccancersasystematicreviewandmetaanalysis AT yixianli associationbetweenhighgalectinexpressionandpoorprognosisinhematologiccancersasystematicreviewandmetaanalysis AT zhenfeitang associationbetweenhighgalectinexpressionandpoorprognosisinhematologiccancersasystematicreviewandmetaanalysis AT tiantianshe associationbetweenhighgalectinexpressionandpoorprognosisinhematologiccancersasystematicreviewandmetaanalysis |